



CLINICAL MEDICAL POLICY	
<b>Policy Name:</b>	Pharmacogenomic Testing for Warfarin Response (NCD 90.1)
<b>Policy Number:</b>	MP-044-MC-PA
<b>Responsible Department(s):</b>	Medical Management
<b>Provider Notice/Issue Date:</b>	10/01/2024; 10/01/2023; 11/01/2022; 10/15/2021; 10/19/2020; 11/18/2019; 11/15/2018; 06/01/2018
<b>Effective Date:</b>	11/01/2024; 11/01/2023; 12/01/2022; 11/15/2021; 11/16/2020; 11/18/2019; 11/15/2018; 06/01/2018
<b>Next Annual Review:</b>	09/2025
<b>Revision Date:</b>	09/18/2024; 09/20/2023; 09/21/2022; 09/15/2021; 09/16/2020; 09/18/2019; 09/19/2018
<b>Products:</b>	Pennsylvania Medicare Assured
<b>Application:</b>	All participating and nonparticipating practitioners and facilities unless contractually precluded
<b>Page Number(s):</b>	1 of 4

#### Policy History

Date	Activity
11/01/2024	Provider Effective date
09/18/2024	QI/UM Committee review
09/18/2024	Annual Review: No changes to clinical criteria. Updated CMS hyperlink. Updated 'Reference Sources' section.
11/01/2023	Provider Effective date
09/20/2023	QI/UM Committee review
09/20/2023	Annual Review: No changes to clinical criteria. Updated CMS hyperlink. Updated 'Reference Sources' section.
12/01/2022	Provider Effective date
09/21/2022	QI/UM Committee review
09/21/2022	Annual Review: No changes to clinical criteria. Updated CMS hyperlinks, added LCA & related LCD hyperlinks. Corrected CPT code 31355 code description. Updated 'Reference Sources' section.
11/15/2021	Provider effective date
09/15/2021	QI/UM Committee review
09/15/2021	Annual Review: Added place of service statement. Ensured all links were active and working. Reviewed CMS, no new updates to NCD or coding.
03/01/2018	Initial policy developed

## **Disclaimer**

Highmark Wholecare<sup>SM</sup> medical policy is intended to serve only as a general reference resource regarding coverage for the services described. This policy does not constitute medical advice and is not intended to govern or otherwise influence medical decisions.

## **Policy Statement**

Highmark Wholecare<sup>SM</sup> does not provide coverage for genetic testing for warfarin therapy initiation under the medical-surgical benefits of the Company's Medicare products. Highmark Wholecare<sup>SM</sup> may only provide coverage for pharmacogenomic testing of CYP2C9 or VKORC1 alleles to predict warfarin responsiveness in alignment with the CMS Coverage with Evidence Development (CED).

This policy is designed to address medical necessity guidelines that are appropriate for the majority of individuals with a particular disease, illness or condition. Each person's unique clinical circumstances warrant individual consideration, based upon review of applicable medical records.

## **Procedures**

1. Please review the specific National Coverage Determination (NCD), Local Coverage Determination (LCD), and/or Local Coverage Article (LCA) information, as well as other CMS sources, using the links below.
2. Post-payment Audit Statement  
The medical record must include documentation that reflects the medical necessity criteria and is subject to audit by Highmark Wholecare<sup>SM</sup> at any time pursuant to the terms of your provider agreement.
3. Place of Service  
Please refer to the NCD, LCD, LCA, and/or CMS guidelines for the proper place of service for pharmacogenomic testing for warfarin response.

## **Coverage Determination and Links**

Highmark Wholecare<sup>SM</sup> follows the coverage determinations made by CMS as outlined in either the NCD or the state-specific LCD/LCA.

### CMS Link

- [CMS Website](#)

### NCD/LCD Links:

- [NCD: Pharmacogenomic Testing for Warfarin Response \(90.1\)](#)
- There are no current LCDs related to this topic.
- Related LCD: [Pharmacogenomics Testing \(L39063\)](#)

Related Article Link:

- [Billing and Coding: Pharmacogenomics Testing \(A58801\)](#)

Field Code Changed

Transmittals:

- [Transmittal 111: Pharmacogenomic Testing for Warfarin Response](#)
- [Pub 100-04 Medicare Claims Processing \(Transmittal 1889\)](#)

## Reference Sources

Centers for Medicare and Medicaid Services (CMS). National Coverage Determination (NCD) Pharmacogenomic Testing for Warfarin Response (90.1). Effective date August 3, 2009. Implementation date April 5, 2010. Accessed on August 28, 2023.

Centers for Medicare and Medicaid Services (CMS). Local Coverage Determination (LCD) Pharmacogenomics Testing (L39063). Original Effective date December 12, 2021. Accessed on August 28, 2023.

Centers for Medicare and Medicaid Services (CMS). Local Coverage Article (LCA) Billing and Coding: Pharmacogenomics Testing (A58801). Original Effective date December 12, 2021. Revision Effective date February 7, 2022. Accessed on August 28, 2023.

Centers for Medicare and Medicaid Services (CMS). Manual System Pub 100-03 Medicare National Coverage Determinations, Transmittal 111. December 18, 2009. Accessed on August 28, 2023.

Centers for Medicare and Medicaid Services (CMS). Manual System Pub 100-04 Medicare Claims Processing, Transmittal 1889. January 8, 2010. Accessed on August 28, 2023.

## Coding Requirements

Procedure Code

HCPSC Code	Description
G9143	Warfarin responsiveness testing by genetic technique using any method, any number of specimen(s)

Noncovered Procedure Codes

CPT Code	Description
81227	CYP2C9 (cytochrome P450, family 2, subfamily C, polypeptide 9) (eg, drug metabolism), gene analysis, common variants (eg, *2, *3, *5, *6)
81355	VKORC1 (vitamin K epoxide reductase complex, subunit 1) (eg, warfarin metabolism), gene analysis, common variant(s) (eg, -1639G>A, c.173+1000C>T)

**Note:** HCPSC modifier 'QO' is required when the service is provided in a clinical research study that is in an approved clinical research study.

Diagnosis Codes

ICD-10 Code	Description
Z00.6	Encounter for examination for normal comparison and control in clinical research program
Z79.01	Long-term (current) use of anticoagulants

**Reimbursement**

Participating facilities will be reimbursed per their Highmark Wholecare<sup>SM</sup> contract.